Lung Cancer Treatment Studies Presented in Seoul
Researchers showcased three experimental therapies for lung cancer at the 2026 World Conference on Lung Cancer.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you feel encouraged by recent progress in targeted therapies for advanced lung cancer?
In September 2026, researchers at the World Conference on Lung Cancer in Seoul presented findings on three new therapies for advanced lung cancer. These treatments target specific genetic mutations and protein markers to improve patient outcomes.
Why it matters
These results offer new therapeutic pathways for patients with advanced lung cancer who often have limited treatment alternatives. The data highlights potential improvements in survival rates and tumor responses for both NSCLC and SCLC.
Trials showed zidesamtinib achieved a 94% response rate in ROS1-positive NSCLC patients, while combination dosing with izalontamab brengitecan reached a 100% response rate in its optimal cohort. Additionally, risvutatug rezetecan and tambotatug pelitecan extended survival compared to topotecan.
The players
World Conference on Lung Cancer
This annual international event serves as a primary forum for researchers to present advances in the diagnosis and treatment of lung malignancies.
The details
The studies evaluated zidesamtinib for blocking gene rearrangements, while risvutatug rezetecan and tambotatug pelitecan targeted the B7-H3 protein on SCLC cells. Participants included 154 patients for the izalontamab brengitecan study, 461 in the ARTEMIS-008 trial, and 451 in the TAISHAN-302 trial.
Timeline
The World Conference on Lung Cancer took place in 2026.
The Big Picture
This research follows a pattern set by studies targeting the B7-H3 protein, which has become a focal point for developing more effective therapies against resistant lung tumors.
These findings provide a foundation for future treatment options that may eventually expand clinical care for patients with advanced lung cancer. Physicians and patients will look for further data to determine how these therapies integrate into standard oncology protocols.
The takeaway
These clinical results represent a significant step forward in personalized oncology for specific lung cancer subtypes. Patients and healthcare providers should monitor future regulatory updates to see when these treatments move from trial phases into clinical practice.
Further reading
Explore more ongoing clinical breakthroughs in our Cancer section.
Live Poll
Do you feel encouraged by recent progress in targeted therapies for advanced lung cancer?
